Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab for aggressive developmental vascular tumors
2007-005199-15Phase 2Active
- Sponsor
- Sant Joan de Déu Hospital
- Start
- Dec 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab in vascular abnormality, Congenital vascular anomaly (CVA) and vascular neoplasm, sponsored by Sant Joan de Déu Hospital. Primary endpoint: Objective response rate. Started Dec 2007; status: active.
02
Drugs
bevacizumab
03
Conditions
vascular abnormalityCongenital vascular anomaly (CVA)vascular neoplasm
Beyond the preview
Go deeper on 2007-005199-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-005199-15.